WIA
ACRV icon

Wealthedge Investment Advisors’s Acrivon Therapeutics ACRV Stock Holding History

Wealthedge Investment Advisors’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-56,467
Closed -$115K – 145
2025
Q1 		$115K Buy
56,467
+45,610
+420% +$246K 0.05% 172
2024
Q4 		$65.4K Buy
+10,857
New +$78.9K 0.03% 168

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wealthedge Investment Advisors's ACRV Position: Q2 2025 in Review

Wealthedge Investment Advisors sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 56,467 shares — an estimated $115K sold.

Wealthedge Investment Advisors first reported a position in ACRV in Q4 2024 and held it in 2 quarters. The position peaked at $115K in Q1 2025. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

  • Wealthedge Investment Advisors reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wealthedge Investment Advisors sold 56,467 Acrivon Therapeutics shares in Q2 2025, an estimated $115K.
  • Wealthedge Investment Advisors first reported a position in Acrivon Therapeutics in Q4 2024 and held it in 2 quarters.
  • Wealthedge Investment Advisors's Acrivon Therapeutics position peaked at $115K in Q1 2025.
  • 53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on Wealthedge Investment Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.